Pharmaceutical

Enquiry IconContact Us

The global pharmaceutical industry is undergoing a consolidation phase in order to combat price pressure, competition and patent cliffs. Innovation is of vital importance for steady growth of pharmaceutical companies. Pharmaceutical companies have been mainly dependent on a few blockbuster molecules. However,with rapid decline in research and development (R&D) productivity and non-conducive regulatory environment, companies need to find different avenues of growth. The patent expiry of blockbuster drugs is expected to pave way for generics. Due to difference in genetic composition of varied individuals, innovation is becoming more complex.This is influencing players offering complementary products and services to collaborate for new product development.

There are four major factors that are impacting the value creation in pharmaceutical industry:

  • Market
    • Stress from patent expiries, niche marketing, and patient-centricity is challenging the growth plans of pharmaceutical companies. Moreover, in emerging markets, companies face strong competition from local players,who sell product at a much lower cost. To counter the same global companies need to significantly reduce their profit margins.
  • Technology
    • Rapid integration of healthcare and information technology is posing threat for current blockbuster drugs
    • Products based on new technologies offer superior properties and are more efficient as compared to existing products in the market
  • Regulation
    • There is constant price pressure from governments to meet demands of growing number of patients
    • Emerging markets have regulatory uncertainty, where decisions are made to protect the interests of the general population
    • Moreover, governments, especially in emerging economies are encouraging pharmaceutical companies to focus on preventive measures for diseases, which involves major investments
  • Innovation
    • Need for innovative products or therapies is rising constantly due to rising pressure of patent-cliff coupled with reducing profit margins
    • Identification of new bacterial and viral strains is driving the need for novel drugs

Demand for personalized medicines is increasing in order to ensure effective treatment of various diseases

Investments in R&D for oncology and NCDs are increasing globally in order to provide cost-effective solutions available to ailing patients.

Market Challenges

The industry is facing certain challenges such as patent cliff, cost pressure and regulatory uncertainties across the globe. This is hindering market growth to a certain extent. Moreover, regulatory authorities are becoming more stringent with the drug approval process. However, with respect to drugs for rare diseases, the FDA has offered a fast-track approval process. Moreover, demand for cost-effective treatment for chronic and non-communicable diseases such as diabetes, hypertension, thyroid disorder, obesity, and cancer is increasing. However, there is a dearth of strong products in the pipeline that offer better treatment option with fewer side effects. The fear of side effects and long-term treatment costs is encouraging patients to shift to alternative therapies.

Combating Challenges

Market players need to combat these challenges and keep their pace with the industry to sustain their market share. Mergers, acquisitions, and divestitures of products, companies or business division is a rapidly emerging trend in the market to combat prevalent challenges in the market.Companies are more focused in terms of therapy areas and hence, are divesting less focused therapy businesses. A good example is the swap deal between GSK and Novartis in 2015.

Moreover, pharmaceutical companies are investing in consumer health products,with increasing consumer’s health awareness and emerging trend of self-medication. These trends are encouraging pharmaceutical companies to enter the OTC market and leverage their brand equity among the doctors, chemists and consumers. Companies such as GlaxoSmithKline, Cipla, Pfizer, Merck, Sun Pharma, and Abbott have a focused division or subsidiary for consumer healthcare products and markets.

Moreover, to combat increasing cost pressure, companies are evolving their distribution channel. Establishing facilities or presence through collaboration in regional markets has helped companies meet local demand with reduced costs and delivery time. Emergence of e-pharmacy has resulted in creation of a separate team in the organization to service consumers ordering medicines online. Moreover, companies are connecting with consumers through social media, which helps improve brand visibility. The distribution channel has thus evolved significantly from the decade old channel consisting of only wholesalers and physical retail shops.

Patient-centricity

Patients are increasingly becoming well informed and organized, sometimes demanding for a particular product from prescribers. Therefore, companies need to be more patient-centric in their approach and provide quality care to consumers. Pharmaceutical companies are focusing on established direct to consumer distribution channels and establishing a more strong relationship with them. Moreover, companies are creating a good purchase experience for consumers through different offerings such as post-purchase medical services, engaging the patient through social media and events, and providing regular product alerts and refilling services.

Growth in Emerging Economies

The pharmaceutical industry is rapidly expanding in emerging economies such as Asia Pacific, Africa, and Latin America. These regions possess immense potential for growth of pharmaceutical companies, owing to inadequate access to medicines, growing population and increasing incidence of non-communicable diseases (NCDs). Besides, demand for contract research and manufacturing is also high in these regions. China and India are the largest emerging markets for CRO and CMO. Companies are highly dependent on China for API supply owing to low purchase cost. Overdependence on a single country can pose a challenge for the pharmaceuticals sector in the near future. Therefore, other emerging countries such as India, Brazil and South Africa are encouraging investments in their country. Besides, global companies are establishing their facilities in Asia Pacific, Middle East and Latin America regions to enable close monitoring and servicing of lucrative regional markets.

Conclusion

Pharmaceutical companies need to focus on an integrated, patient-centric, value-driven approach along with technology integration and strategic partnerships in order to capitalize on lucrative growth opportunities in the market. Major global players in the market include Pfizer Inc., Merck & Co., Inc., Bayer AG, GlaxoSmithKline plc., Sanofi, F. Hoffmann-La Roche AG, AstraZeneca plc. and Novartis AG.

There is a paradigm shift in process in the global pharmaceutical industry from product to a ‘Prodice’ (Product and Service) model, to offer affordable, accessible and quality care to patients.

View More

Pharmaceutical Published Insights

Coherent Market Insights

U.S. Vasopressin Market, by Type (Intravenous Injection, Intramuscular Injection, Subcutaneous Injection, and Others), by Application (Anti-diuretic Hormone Deficiency, Gastrointestinal Bleeding, Vasodilatory Shock, Ventricular Tachycardia, and Fibrillation), and by End User (Hospitals, Dental Clinics, and Others) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published Date : Mar 2022

Vasopressin is antidiuretic hormone. It is naturally secreted by the pituitary gland, which acts on the kidneys and blood vessels. Vasopressin can be used to treat diabetes insipidus through different routes of administration such as intravenous injection, intramuscul... View more

Coherent Market Insights

U.S. P2Y12 Inhibitors Market, by Drug (Clopidogrel, Ticlopidine, Ticagrelor, Prasugrel, Cangrelor, and Others), by Route of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Percutaneous Coronary Interventions, Myocardial Infarction, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published Date : Mar 2022

P2Y12 is a chemoreceptor for adenosine diphosphate (ADP) that belongs to the Gi class of a group of G protein-coupled (GPCR) purinergic receptors. The P2Y12 receptor is involved in platelet aggregation and is thus a biological target for the treatment of thromboemboli... View more

Coherent Market Insights

Central Precocious Puberty Market, by Drug (Leuprolide Acetate, Triptorelin, Histrelin Acetate, and Nafarelin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published Date : Mar 2022

Central Precocious Puberty (CPP) is referred to as gonadotropin-dependent precocious puberty. It is an endocrine-related developmental disease characterized by the onset of pubertal changes with the development of secondary sexual characteristics, accelerated growth, ... View more

Coherent Market Insights

Colombia, Chile and Peru Wilson’s Disease Treatment Market, by Drugs (D-Penicillamine, Trientine, and Zinc Acetate), by Distribution Channel (Hospital Pharmacies and Government Distribution Channels), and by Country (Colombia, Chile, and Peru) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published Date : Mar 2022

Wilson’s disease is a rare genetic disorder characterized by excess copper stored in various body tissues, particularly in the liver, brain, and corneas of the eyes. The disease is progressive, and if lef... View more

Coherent Market Insights

Adoptive Cell Therapy Market, by Type (CAR-T, TCR-T, NK, and TIL), By Application (Lymphoma, Leukemia, and Others), by End User (Hospitals and Cancer Treatment Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published Date : Mar 2022

Adoptive cell therapy (ACT) is a kind of immunotherapy, in which T cells are genetically modified to express a chimeric antigen receptor (CAR) or T cell receptor (TCR). Adoptive cell therapy has made a great difference in treating multiple types of tumors. Some approaches of ACT  involve dir... View more

Coherent Market Insights

Duck Medicine and Vaccines Market, by Type (Medicine and Vaccines), by Application (Farm and Government), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published Date : Mar 2022

Ducks are relatively resistant to disease, but they have been known to carry diseases that are infectious to other types of poultry. However, some of the common diseases in ducks include duck virus hepatitis, duck plague, pasteurellosis, and aflatoxicosis. As there is... View more

Coherent Market Insights

U.S. Naloxone Market, by Drug Type (Branded and Generic), by Route of Administration (Intranasal Administration, Intramuscular Administration, Intravenous Administration, and others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published Date : Mar 2022

Naloxone is an opioid overdose reversal medicine used to treat morphine and heroin overdoses. It is an opioid antagonist that is classified as a prescription medicine by the U.S. Food and Drug Administration (FDA). Some countries, including Italy and Australia, have r... View more

Coherent Market Insights

Antibody Cocktails Market, by Type (Monovalent Antibody and Polyvalent Antibody), by Indication (COVID-19, Cancer, HIV, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published Date : Feb 2022

An antibody is a protein made by immune cells that is of or specific shape and size so that it can attach itself to a specific point on a particular foreign substance, such as a virus or bacteria. By attaching, the antibody can potentially prevent these invaders from ... View more

Coherent Market Insights

Africa Injectable Drugs Market, by Molecule Type (Large Molecule and Small Molecule), by Route of Administration (Intravenous, Intramuscular, Sub-cutaneous, and Others, by End User (Hospitals, Specialty Clinics, and Others), and by Country/Region (South Africa, Central Africa, and North Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published Date : Feb 2022

Injectable pharmaceutical drug delivery system can be used as an alternative to oral drug delivery system. An injection is considered a form of parenteral drug administration, and it allows the medication to be absorbed more rapidly. ... View more

Coherent Market Insights

Pyrimethamine Market, by Indication (Toxoplasmosis, Malaria, and Others), by Route of Administration (Parenteral and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published Date : Feb 2022

Pyrimethamine is listed as one of the top drugs on the World Health Organization's essential drugs list. Pyrimethamine selectively inhibits the Plasmodium form of dihydrofolate reductase and reduces the production of folic acid, which is necessary for the synthesis of... View more

Coherent Market Insights

U.S. Triptorelin Market, by Product Type (Triptorelin Pamoate, Triptorelin Acetate, and Triptorelin Embonate), by Application (Prostate Cancer, Radical Prostatectomy, Endometriosis, Salivary Gland Cancer, and Central Precocious Puberty), and by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published Date : Feb 2022

The Gonadotropin-releasing hormone (GnRH) agonists are considered to have greater safety and efficacy profile than anti-androgens and estrogens and are among various therapies of achieving medical castration. Furthermore, the drug is mostly implanted in the body in th... View more

Subscribe Newsletter

Kindly subscribe for our latest news & articles.